Nidogen-1, a Player in KMT2A-Rearranged Pediatric Acute Myeloid Leukemia
Authors:
- Jolien VanhoorenJVJolien Vanhooren
- Larissa DenewethLDLarissa Deneweth
- Luca PagliaroLuca Pagliaro
- Zhiyao RenZRZhiyao Ren
- Mariateresa GiaimoMGMariateresa Giaimo
- Rafaella ZamponiRZRafaella Zamponi
- Giovanni RotiGRGiovanni Roti
- Barbara DepreterBDBarbara Depreter
- Mattias HofmansMHMattias Hofmans
- Barbara De MoerlooseBMBarbara De Moerloose
- Tim LammensTLTim Lammens
Open Access
- 26 March 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3011
Abstract
Despite advances in outcome, one third of children with acute myeloid leukemia (AML) relapse, and less than half will achieve long-term survival. Relapse in AML has been shown to be driven in part by leukemic stem cells (LSCs), highlighting the unmet medical need to better characterize and target this therapy-resistant cell population. Micro-array profiling of pediatric AML subpopulations (LSCs and leukemic myeloblasts) and their healthy counterparts revealed nidogen-1 (NID1) as expressed in both leukemic subpopulations while absent in the hematopoietic stem cell. Using the TARGET dataset including pediatric AML patients (n = 1025), NID1 expression showed a correlation with worse event-free survival and KMT2A rearrangements. Drug response profiling of a NID1 knockdown model demonstrated differential sensitivity to HSP90 inhibition. RNA sequencing and gene set enrichment analysis between NID1high and NID1low phenotypes showed involvement of NID1 in mitochondrial metabolic pathways known to be enriched in LSCs. Altogether, this study highlights NID1 as a novel oncogene associated with worse EFS and metabolic LSC phenotype in AML. NID1 could serve as a biomarker and aid in further mapping LSCs to establish therapeutic strategies tackling the high relapse rates in pediatric AML.Keywords
Funding Information
- Kom op tegen Kanker
- vzw Kinderkankerfonds
- MeToYou Foundation
This publication has 35 references indexed in Scilit:
- Integrative single‐cell expression and functional studies unravels a sensitization to cytarabine‐based chemotherapy through HIF pathway inhibition in AML leukemia stem cellsHemaSphere, 2024
- HIF-1α induced NID1 expression promotes pulmonary metastases via the PI3K-AKT pathway in salivary gland adenoid cystic carcinomaOral Oncology, 2022
- Nidogen: A matrix protein with potential roles in musculoskeletal tissue regenerationGenes & Diseases, 2021
- Extinguishing the Embers: Targeting AML MetabolismTrends in Molecular Medicine, 2021
- Nidogen 1‐Enriched Extracellular Vesicles Facilitate Extrahepatic Metastasis of Liver Cancer by Activating Pulmonary Fibroblasts to Secrete Tumor Necrosis Factor Receptor 1Advanced Science, 2020
- Acute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem CellsCell Reports, 2020
- Response‐guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML‐01Pediatric Blood & Cancer, 2019
- Defining a Cancer Dependency MapCell, 2017
- A 17-gene stemness score for rapid determination of risk in acute leukaemiaNature, 2016
- Structural elucidation of full-length nidogen and the laminin–nidogen complex in solutionMatrix Biology, 2014